All Stories

  1. Pancreatic Ductal Adenocarcinoma After Hepatitis C Infection
  2. Data from Differences in Pathology, Staging, and Treatment between HIV<sup>+</sup> and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
  3. Supplementary Tables 1-9 from Differences in Pathology, Staging, and Treatment between HIV<sup>+</sup> and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
  4. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes
  5. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
  6. Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV
  7. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
  8. COVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration
  9. Identification of hepatic steatosis among persons with and without HIV using natural language processing
  10. Development and Validation of Case-Finding Algorithms to Identify Pancreatic Cancer in the Veterans Health Administration
  11. Postoperative Outcomes Associated with the Timing of Surgery After SARS-CoV-2 Infection
  12. Comparison of Stage I Non–Small-Cell Lung Cancer Treatments for Patients Living With HIV: A Simulation Study
  13. Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout
  14. Differences in COVID-19 testing and adverse outcomes by race, ethnicity, sex, and health system setting in a large diverse US cohort
  15. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
  16. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
  17. SARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts
  18. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
  19. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV
  20. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
  21. HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs
  22. Risks of Opportunistic Infections in People With Human Immunodeficiency Virus With Cancers Treated With Chemotherapy
  23. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015
  24. Statin exposure and risk of cancer in people with and without HIV infection
  25. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma
  26. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index
  27. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study
  28. Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans
  29. Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort Study
  30. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years
  31. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
  32. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
  33. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
  34. HIV and cancer in the Veterans Health Administration System
  35. Short-term outcomes for lung cancer resection surgery in HIV infection
  36. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
  37. Association of Viral Suppression With Lower AIDS-Defining and Non–AIDS-Defining Cancer Incidence in HIV-Infected Veterans
  38. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America
  39. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study
  40. Does radiotherapy still have a role in unresected biliary tract cancer?
  41. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era
  42. Gleason grade in HIV+ versus uninfected prostate cancer patients in the Veterans Aging Cohort study.
  43. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS
  44. Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults
  45. Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus–Monoinfected Patients
  46. Cancer Incidence in HIV-Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 Code Diagnoses
  47. Time trends in glioblastoma multiforme survival: the role of temozolomide
  48. HIV infection, aging, and immune function
  49. HIV as an independent risk factor for incident lung cancer
  50. FIB-4 Index Is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patients
  51. HIV Transmission Rates in Thailand: Evidence of HIV Prevention and Transmission Decline
  52. Rehospitalization among Elderly Patients with Thyroid Cancer after Thyroidectomy are Prevalent and Costly
  53. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients